Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: VRDN) | Delayed: 22.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.82 | 52 Week High | $ | |||
| Open | $22.82 | 52 Week Low | $ | |||
| Day High | $22.82 | P/E | N/A | |||
| Day Low | $22.82 | EPS | $ | |||
| Volume | 8,476 | |||||
